

Contact Info:

Joseph D. Fondacaro, Ph.D.

513-636-7695

jdfonda@chmcc.org

Antibodies Now Available Directly From The Source

Seven Hills Bioreagents eliminates the need to deal with resellers

Cincinnati, OH – December 14, 2005 – Monoclonal and polyclonal antibodies in lung and muscle development have recently been made available from Seven Hills Bioreagents (SHB), a venture of Cincinnati Children's Research Foundation (CCRF), directly from its web site at <http://www.sevenhillsbioreagents.com>.

SHB was established with the mission of providing high quality reagents generated by the expert scientists at CCRF to the broader scientific community. Historically, many of these reagents have been commercialized through licensing to companies which then resell the materials to the marketplace.

Because the reagents available from SHB are supplied by expert researchers who are actively using them in their own laboratories, SHB is able to provide unprecedented product support . In addition, because there is no “middleman”, Seven Hills Bioreagents can supply reagents at very competitive prices with fast, personalized service.

Dr. Clarissa Naftzger, an immunologist with extensive background in biotechnology, was hired in 2003 to spearhead this initiative. "This is a novel initiative for our research institution that should directly benefit research programs at Cincinnati Children's Hospital while providing valuable tools to scientists throughout the world," Naftzger said. “Many of the antibodies we’re now supplying directly have been sold through third parties for years,” she added.

Additionally, a Scientific Advisory Board composed of leading scientists in the Cincinnati medical research community is providing guidance on the development of new products. “This new enterprise is an alternative commercial strategy to traditional licensing agreements” said Joseph Fondacaro, Ph.D., Director of CCRF’s Office of Intellectual Property.

The first products available include antibodies developed in the laboratories of Dr. Jeffrey Whitsett and Dr. James Lessard at Cincinnati Children’s Hospital Medical Center (CCHMC). Dr. Whitsett is a world-renowned leader in the field of pulmonary biology and has developed numerous antibodies in his laboratory to study lung development. CCHMC currently has more than 10 license agreements with different companies to market many of the antibodies Dr. Whitsett has developed, including the TTF-1 antibody used widely in the diagnosis of lung adenocarcinoma.

Dr. Lessard studies muscle development and the role of muscle actins. The antibody C4 was developed in his laboratory and is widely used as a control antibody by researchers in numerous fields; it has been licensed by CCHMC for over 10 years.

Details of each of the 14 products initially available and registration for product updates can be found at the SHB web site, <http://www.sevenhillsbioreagents.com>.

The Children's Hospital Research Foundation (CHRF) in Cincinnati, Ohio, founded in 1931, has been rated as one of the most outstanding pediatric research institutions in the nation. The CHRF is the largest pediatric research program in the Midwest, conducting both basic and clinical research. Its scientists have been responsible for such breakthrough discoveries as the Sabin oral polio vaccine, the first practical heart-lung machine that made open heart surgery possible, and discovery of key ingredients of the surfactant preparation used throughout the world to save the lives of thousands of premature infants each year.

###